800.850.4306

Medication List
How to Prescribe

FYARRO (sirolimus protein-bound particles for injectable suspension) (albumin-bound), FDA Approved for Treatment of Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor, Available at Biologics by McKesson

  • Biologics by McKesson was selected as a specialty pharmacy provider for FYARRO, approved for adults with locally advanced unresectable or metastatic malignant PEComa.

REZLIDHIA (olutasidenib), FDA-Approved for Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia, Available at Biologics by McKesson

  • Biologics by McKesson joined a limited distribution network for REZLIDHIA, approved for adults with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation.

KRAZATI® (adagrasib), FDA Approved for Treatment of Advanced Non-Small Cell Lung Cancer Harboring the KRASG12C Mutation, Available at Biologics by McKesson

  • Biologics by McKesson joined a limited distribution network for KRAZATI, approved for previously treated adults with locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer.

ELAHERE™ (mirvetuximab soravtansine-gynx), FDA Approved for Platinum-Resistant Ovarian Cancer, Available at Biologics by McKesson

  • Biologics by McKesson became the sole specialty pharmacy provider for ELAHERE, approved for adults with FRα-positive, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.

Biologics by McKesson is now the Exclusive Specialty Pharmacy Provider of XERMELO (telotristat ethyl), an FDA Approved Therapy for Carcinoid Syndrome Diarrhea

  • Biologics by McKesson became the exclusive specialty pharmacy provider for XERMELO, used with somatostatin analog therapy to treat carcinoid syndrome diarrhea in adults.

VONJO (pacritinib), FDA Approved for Treatment of Intermediate or High-risk Myelofibrosis, Available at Biologics by McKesson

  • Biologics by McKesson was selected as a specialty pharmacy provider for VONJO, approved for adults with intermediate- or high-risk myelofibrosis and severe thrombocytopenia.
Load More